Metabolic Disease

CIR Biopharma's in vivo pharmacodynamics team has rich experience in constructing animal models of metabolic diseases and in vivo pharmacology research, and has constructed a variety of metabolic disease models. To meet the differentiated needs of customers, the team can provide customized services to develop suitable animal models and appropriate in vivo pharmacodynamic study for our customers.


Osteoporosis models

  • Osteoporosis model of castrated female rat

  • Glucocorticoid-induced osteoporosis model in rats

  • Retinoic acid A induced osteoporosis model in rats


Cholestasis models

  • Bile duct ligation cholestasis model in rats

  • DDC-induced cholestasis model in mice


Diabetes models

  • ZDF rat diabetes model

  • db/db mouse diabetes model

  • ob/ob mouse diabetes model

  • STZ indued rat/mouse diabetes model

  • STZ and  high-fat diet combination induced rat/mouse diabetes model

  • db/db mouse diabetic nephropathy model

  • STZ and high-fat diet combination induced rat/mouse diabetic nephropathy model


Liver disease models

  • Non-alcoholic steatohepatitis（NASH）mouse model

  • TAA-induced mouse liver fibrosis model


Obesity model

  • High-fat diet induced obesity model in C57BL/6 mice

  • High-fat diet induced obesity model in SD rats


Hyperlipidemia models

  • High-fat diet induced hyperlipidemia model in golden hamsters

  • High-fat diet induced hyperlipidemia model in C57BL/6 mice

  • High-fat diet induced hyperlipidemia model in ApoE-/- mice

  • High-fat diet induced hyperlipidemia model in LDLR-/- mice

  • High-fat diet induced hyperlipidemia model in SD rats


Sarcopenia models

  • Posterior fixation induced mouse sarcopenia model

  • Suspension induced mouse sarcopenia model

  • Glucocorticoid-induced mouse sarcopenia model